Menu Search
Equities

Evolent Health Inc

9EH:DUS

Evolent Health Inc

Actions
  • Price (EUR)10.70
  • Today's Change0.10 / 0.94%
  • Shares traded--
  • 1 Year change-59.16%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 18:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Evolent Health Inc had net income fall 489.86% from a loss of 19.16m to a larger loss of 113.04m despite revenues that grew 45.26% from 1.35bn to 1.96bn over the same period.
Gross margin15.96%
Net profit margin-2.93%
Operating margin-2.61%
Return on assets-2.79%
Return on equity-9.77%
Return on investment-3.58%
More ▼

Cash flow in USDView more

In 2023, Evolent Health Inc did not generate a significant amount of cash. Cash Flow from Financing totalled 281.34m or 14.33% of revenues. In addition the company generated 142.58m in cash from operations while cash used for investing totalled 415.54m.
Cash flow per share0.1274
Price/Cash flow per share90.48
Book value per share10.66
Tangible book value per share-5.29
More ▼

Balance sheet in USDView more

Evolent Health Inc has a Debt to Total Capital ratio of 32.85%, a lower figure than the previous year's 47.18%.
Current ratio1.04
Quick ratio--
Total debt/total equity0.4892
Total debt/total capital0.3285
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.